(Hypertension. 1999;34:1086-1090.)
© 1999 American Heart Association, Inc.
Scientific Contributions |
From the Department of Medicine, MCP Hahnemann University, Philadelphia, Pa.
Correspondence to Bonita Falkner, MD, Department of Medicine, MCP Hahnemann University, 3300 Henry Ave, Suite 128/C, Philadelphia, PA 19129. E-mail: falknerb{at}mcphu.edu
| Abstract |
|---|
|
|
|---|
Key Words: insulin glucose diabetes mellitus blood pressure blacks lipids
| Introduction |
|---|
|
|
|---|
The insulin-resistance syndrome, which consists of high blood pressure (BP), obesity, glucose intolerance (or DM), and dyslipidemia, is strongly associated with cardiovascular disease.3 This metabolic syndrome of impaired insulin glucoregulatory action with hyperinsulinemia also occurs in blacks.4 It has been hypothesized that it is the hyperinsulinemia that emanates from impaired insulin action that contributes to vascular injury through lipid abnormalities and hypertension conferred by excess insulin.3 5 Alternatively, the elevated BP may be a more direct consequence of the tissue resistance to insulin action or insulin resistance.1 Impaired glucose tolerance (IGT) is a component of insulin resistance and is a high-risk status for the development of NIDDM.6 The purpose of this investigation was to determine whether IGT is associated with an increase in BP in young adult blacks.
| Methods |
|---|
|
|
|---|
Procedures
Enrollment assessment consisted of anthropometric measurements
(height, weight, skinfold thickness, and circumference of arm, hips,
thigh, and waist) and BP determination. Casual systolic (first
phase) and diastolic (fifth phase) BP measurements were
obtained by auscultation with a mercury column sphygmomanometer in the
seated position after a 10-minute rest period. The average of 2
determinations was used as the BP (SBP, DBP, and
MBP=DBP+[SBP-DBP]/3, in which SBP indicates systolic blood
pressure; DBP, diastolic blood pressure; MBP, mean blood
pressure) at the time of the metabolic evaluation. With the
use of the anthropometric measurements, body mass index (BMI), percent
body fat, and fat-free mass were calculated.7 An oral
glucose tolerance test (OGTT) was conducted at 8 AM after a
12-hour fast. A fasting blood sample for serum lipids and glucose was
obtained, and then 75 g of glucose solution (Glucola, Ames
Laboratories) was ingested. Blood samples were obtained at 30, 60, 90,
and 120 minutes after ingestion of the glucose load and were assayed
for glucose and insulin concentration. A serum sample was sent to the
Lipid Research Laboratory where total cholesterol, HDL-C,
and total triglycerides were analyzed with standard
enzymatic methods and an automated analyzer (Hitachi 704). HDL
was isolated according to the method of Bachorik et al.8
LDL cholesterol was calculated by the Friedewald
equation.9 Apolipoprotein A-1 and apolipoprotein B were
assayed turbidimetrically with commercial antibodies
(Boehringer-Mannheim).
The euglycemic hyperinsulinemic clamp was used to measure insulin-stimulated glucose use.10 11 Each subject returned to the clinical research unit for the euglycemic clamp procedure at 8 AM after a 12-hour overnight fast. The euglycemic clamp procedure was conducted according to methods previously described.12 4 In brief, the subject rested for at least 20 minutes after placement of venous catheters for infusion and sample withdrawal. Before the onset of euglycemic hyperinsulinemia, 3 samples were withdrawn for determination of fasting plasma glucose and fasting insulin concentration. Hyperinsulinemia was established with a primed constant infusion of insulin with the method of Rizza et al11 to compute the priming dose and infusion rate of insulin. The target clamped-insulin concentration was 70 to 80 µU/mL of insulin above fasting concentration, which was achieved with an infusion rate of 40 mU/m2 · min.11 Glucose infusion was administered as 20% dextrose. The precise glucose concentration in the 20% dextrose stock solution was measured, and this value was used in the calculation of the glucose infusion rate with the negative feedback equation of DeFronzo et al,10 with plasma glucose sampling every 10 minutes. Euglycemic hyperinsulinemia was maintained for 120 minutes. During the final 60 minutes of steady-state hyperinsulinemia, insulin-stimulated glucose use was determined from the glucose infusion rate. The coefficient of variation for clamped plasma glucose concentration was <5% during the final 60 minutes of the procedure. Insulin-stimulated glucose use was computed as the mean glucose infusion rate during the final 60 minutes of hyperinsulinemia and expressed as mg/Kg · min (M). With the use of the anthropometric measures, we computed the fat-free mass for each subject, and insulin-stimulated glucose use was expressed as mg/Kg of fat-free mass · min (M'). An index of insulin sensitivity (M/I) was computed by dividing the glucose infusion rate (M) by the mean insulin level achieved during steady-state hyperinsulinemia, in which I indicates the subject mean plasma insulin concentration during the final 60 minutes of the clamp.
Glucose was administered as 20% dextrose in water (Abbott). Insulin (Eli Lilly) was mixed with normal saline to a concentration of 1000 mU/mL. All solutions were delivered by syringe pumps (model 22, Harvard). Plasma glucose concentration was analyzed with the glucose oxidase technique (YSI Model 27, Glucostat). Plasma insulin concentration was determined with a solid phase radioimmunoassay (Coat-A-Count, Diagnostic Products Corp). The cross-reactivity with proinsulin in this assay is 40% at mid-curve (0 to 500). Plasma insulin concentrations in the study were well below mid-curve. Coefficient of variations for interassay and intra-assay variability for glucose, insulin, and the lipid assays were <5%.
Data Analysis
We used the results of the OGTT on each subject to classify
glucose metabolism status according to the criteria of the
American Diabetes Association.6 With the use of these
criteria, subjects were classified as normal glucose tolerance (NGT),
IGT, or DM. Comparison of group means was performed with a 1-way ANOVA.
The 3 glucose metabolism groups were compared within each
gender separately, with a test for statistically significant linear
trend in means. P values and linearity values <0.05 were
considered statistically significant.
Note that the insulin levels were approximately log normally distributed; therefore, all analyses were performed with the observed values and the logarithmic transformed values for plasma insulin concentration. The P value presented in the results are for the measured insulin values not the logarithmic transformation of the insulin values. Insulin values measured during the OGTT were determined by the examination of the area under the curve of the 4 measurements by the trapezoidal rule to estimate the area. The results obtained by this method did not differ from the unweighted sum of the 4 insulin values. Bivariate correlation analyses with the Pearson correlation coefficient were also applied to all variables, which were examined in 3 sets (1 set for the entire study sample and 1 set for each gender). All cases included in this analysis had complete BP, anthropometric, and OGTT data.
| Results |
|---|
|
|
|---|
|
As shown in Table 1, both weight and BMI increase as metabolic status shifts from NGT to IGT to DM in both men and women. Except for body weight in women, which was marginally significant, the other group differences in weight and BMI were statistically significant and there was a statistically significant linear trend. Note that the mean BMI among the women with NGT was 31.0, a level indicating a substantial amount of obesity despite NGT and BP in the normotensive range. In men, the mean BP was greater in the IGT and DM compared with the NGT. However, the group differences were not statistically significant. In the women, the mean BP was also greater in the IGT and DM groups compared with the NGT group, and these group differences as well as the linear trend reached a high level of statistical significance (P<0.001). We also applied ANOVA for BP in the metabolic groups with BMI as a covariate. With BMI as a covariate, there continued to be statistically significant differences between the groups for SBP (P=0.006), DBP (P<0.02), and MBP (P=0.006).
The measures of insulin resistance according to glucose tolerance classification, as well as the mean values for the entire cohort, are provided in Table 2. These data demonstrate the progression of insulin resistance and hyperinsulinemia as glucose tolerance shifts from normal to impaired. For both men and women, there were statistically significant metabolic group differences (P<0.001) and a significant linear trend (P<0.001).
|
Mean values for the plasma lipids obtained at the time of the OGTT in the metabolic groups, as well as for the entire cohort, are provided in Table 3. In men, no statistically significant differences existed in the lipid parameters between NGT and IGT. In women, there were also no difference in mean lipid levels between NGT and IGT. All mean values were in a normal to low-normal range, despite the degree of obesity and IGT in the 2 groups. However, the DM group of women demonstrated higher total cholesterol, triglyceride, and apolipoprotein B mean values, resulting in statistically significant group differences and a significant linear trend. Thus, substantially altered plasma lipid levels were not detected until diabetic criteria in glucose metabolism were met in this sample of young black adults. With BMI as a covariate in the ANOVA, there continued to be statistically significant differences for total cholesterol (P<0.02) and triglycerides (P=0.03).
|
We have previously demonstrated a significant relationship of insulin resistance with BP in young blacks.12 4 Correlation analyses of the measure of insulin sensitivity from the insulin clamp procedure and BP demonstrated the same relationships in this study. The figure demonstrates the statistically significant correlation of the computed mean BP with the insulin sensitivity index for the entire cohort (r=-0.33, P<0.001). The correlation coefficient is statistically significant for men separately (r=-0.33, P<0.001) and for women separately (r=-0.34, P<0.001). Despite the marginal difference in mean plasma lipid concentration among the 3 metabolic groups, the correlation analyses demonstrated statistically significant correlations of BP with plasma lipids. These correlation coefficients are presented in Table 4. These analyses demonstrate a consistently strong relationship of BP with insulin resistance, and also correlations of BP with lipid alterations in blacks at a young age.
|
| Discussion |
|---|
|
|
|---|
Previous investigations have implicated the hyperinsulinemia of insulin resistance as the mechanism that mediates BP elevation through the action of insulin on increasing sympathetic nervous system activity14 or on increasing renal sodium reabsorption.15 Investigations by Anderson et al16 17 examined the effect of euglycemic hyperinsulinemia during a clamp procedure in both normotensive and hypertensive subjects. Although they demonstrated a significant increase in muscle sympathetic activity in response to the hyperinsulinemia, there was a decrease in BP in both normotensive and hypertensive subjects. There was also a decrease in peripheral vascular resistance, which indicated a vasodilator rather than a pressor effect of insulin. A previous investigation on BP sensitivity to sodium in this black American cohort did detect a significant relationship of plasma insulin with sodium sensitivity, but this relationship was strongly associated with obesity.18 On the other hand, the experimental works of Hall et al19 20 detected no pressor effect of hyperinsulinemia in dogs. Thus, although an increase in sodium retention may contribute to an increase in BP in black Americans, this may not be the only explanation for the excess in hypertension or cardiovascular disease experienced by this minority group.
In humans with normal glucose tolerant, insulin has a vasodilator effect, resulting in an increase in blood flow and a decrease in vascular resistance.21 Studies by Baron et al21 have shown that in insulin resistance associated with obesity and in insulin resistance associated with NIDDM,22 there is a blunted vasodilator response to insulin as well as an attenuated effect of insulin in decreasing vascular resistance. These investigators suggested that there may be a hemodynamic basis for the insulin resistance observed in patients with hypertension.
The above findings of a reduced vasodilator response to insulin in the insulin-resistant conditions of obesity and NIDDM are supported by the observations of Heise et al23 in patients with hypertension and insulin resistance. Compared with normotensive subjects, obese insulin-resistant subjects show a significant attenuation in the increase in leg blood flow during insulin infusion. These investigators also demonstrated a small BP-lowering effect of exogenous insulin in the hypertensive insulin-resistant patients. Together these data support the concept of vascular resistance to the vasodilator action of insulin in insulin-resistant conditions.
Endothelium-dependent vasodilation is abnormal in patients with Type 1 (insulin dependent) DM24 and in patients with NIDDM.25 The endothelial dysfunction may be secondary to underlying mechanisms that result in reduced bioavailability of nitric oxide.25 Concurrent studies of endothelial-mediated vasodilation were not conducted in the present study. However, the upward trend in BP associated with impaired glucose metabolism and insulin resistance suggests that this relationship in this young adult black cohort may be related to vascular or endothelial resistance to insulins vasodilator action.
There may be some limitations to this study, such as the lower number of men than women enrolled and the sample selection. Participants in this study have also participated in previous studies in our laboratory. Although on one hand this sample provides a prospective view on cardiovascular risk, their continuing participation could render the sample less generalizable. Other potential confounding factors that were not controlled include diet, fitness level, smoking, and night-shift work.
It has been estimated that
50% of diabetic subjects already have
some form of significant cardiovascular disease by the
time their diabetes is first diagnosed.26 In this young
black cohort, metabolic alterations predictive of NIDDM
along with lipid and BP risk factors are detectable in 26% of the
cohort by 32 years of age. However, the HDL-C levels appeared to be
conserved in this young black American sample. It is possible that
pathways to vascular injury are underway before clinical expression of
DM or sustained hypertension.
|
| Acknowledgments |
|---|
Received April 19, 1999; first decision May 4, 1999; accepted June 25, 1999.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
A. Jawa, S. Nachimuthu, M. Pendergrass, S. Asnani, and V. Fonseca Impaired Vascular Reactivity in African-American Patients with Type 2 Diabetes Mellitus and Microalbuminuria or Proteinuria Despite Angiotensin-Converting Enzyme Inhibitor Therapy J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 31 - 35. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Golden, J. Ding, M. Szklo, M. I. Schmidt, B. B. Duncan, and A. Dobs Glucose and Insulin Components of the Metabolic Syndrome Are Associated with Hyperandrogenism in Postmenopausal Women: The Atherosclerosis Risk in Communities Study Am. J. Epidemiol., September 15, 2004; 160(6): 540 - 548. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Ziemer, K. J. Berkowitz, R. M. Panayioto, I. M. El-Kebbi, V. C. Musey, L. A. Anderson, N. S. Wanko, M. L. Fowke, C. W. Brazier, V. G. Dunbar, et al. A Simple Meal Plan Emphasizing Healthy Food Choices Is as Effective as an Exchange-Based Meal Plan for Urban African Americans With Type 2 Diabetes Diabetes Care, June 1, 2003; 26(6): 1719 - 1724. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |